Bispecific therapeutics

Discover the groundbreaking findings from a study on bispecific T cell engagers conducted by The Jackson Laboratory. This case study delves into the tools available for assessing cytokine release and tumour growth inhibition. Explore the implications of donor-specific responses and how this knowledge can optimise the development of immunomodulatory therapeutics. Download this Case Study to […]

Discover the groundbreaking findings from a study on bispecific T-cell engagers conducted by The Jackson Laboratory. This case study delves into the tools available for assessing cytokine release and tumour growth inhibition. Explore the implications of donor-specific responses and how this knowledge can optimise the development of immunomodulatory therapeutics. What you will learn: The correlation […]

Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project  who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with over 100 currently in clinical […]

Recent biotechnological advances have fuelled development bispecific antibodies (bsAbs) in the last 10 years. However, the functional analysis of bsAbs during bioprocessing adds a challenge for scientists given the array of bsAbs populated by many different species, comprising many different formats, and that traditional SPR and ELISA methods for bsAbs evaluation are time consuming. Furthermore, […]